The $7.9B that Abbott (ABT) earned from arthritis drug Humira last year could be at risk after Roche's (RHHBY.PK) Actemra performed better in a trial of patients who couldn't take methotrexate. In another study, Bristol-Myers' (BMY) Orencia performed as well as Humira in patients who hadn’t taken a biological rheumatoid arthritis treatment before
Market Data 
Markets 
AI
